ORIGINAL ARTICLE
A study on expression of programmed death ligand-1
in small cell lung carcinoma and correlation with
clinicopathological parameters
1
Department of Pathology, Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow-UP, India
2
Department of Respiratory Medicine, Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow-UP, India
3
Department of Respiratory Medicine, King George’s Medical University, Lucknow-UP, India
Submission date: 2022-07-07
Final revision date: 2023-04-24
Acceptance date: 2024-01-19
Publication date: 2024-03-15
Pol J Pathol 2024;75(1):25-35
KEYWORDS
TOPICS
ABSTRACT
Small cell lung carcinoma (SCLC) is characterized by rapid growth and an aggressive clinical course. Standard therapy regimes have limited effects on disease course; therefore the prognosis of SCLC is poor. In the current study, the frequency of programmed death ligand 1 (PD-L1) expression in SCLC and its correlation with clinico-pathological features were evaluated.
The study included 100 cases of SCLC wherein testing for PD-L1 was done with the SP263 clone on the Ventana benchmark XT system. Cases with > 1% PD-L1 expression in tumour cells or immune cells were categorized as positive.
PD-L1 expression was identified in 14% of cases using the cut-off of ≥ 1%. The tumour proportion score was 10% and the immune proportion score was 9.78% using a cut-off of ≥ 1%. PD-L1 positive expression was more frequent in the male population with age > 40 years. All the patients with positive PD-L1 expression were smokers. In the PD-L1 positive group, presence of necrosis was identified in 71.4% of cases and when compared with the PD-L1 negative subgroup this finding was statistically significant (p = 0.010).
Personalized targeted therapy for cases of SCLC is still under evaluation. The use of immunotherapeutic targets, such as PD-L1, may help to define a new treatment strategy for SCLC. Development of new treatment strategies may improve prognosis and survival.
The study included 100 cases of SCLC wherein testing for PD-L1 was done with the SP263 clone on the Ventana benchmark XT system. Cases with > 1% PD-L1 expression in tumour cells or immune cells were categorized as positive.
PD-L1 expression was identified in 14% of cases using the cut-off of ≥ 1%. The tumour proportion score was 10% and the immune proportion score was 9.78% using a cut-off of ≥ 1%. PD-L1 positive expression was more frequent in the male population with age > 40 years. All the patients with positive PD-L1 expression were smokers. In the PD-L1 positive group, presence of necrosis was identified in 71.4% of cases and when compared with the PD-L1 negative subgroup this finding was statistically significant (p = 0.010).
Personalized targeted therapy for cases of SCLC is still under evaluation. The use of immunotherapeutic targets, such as PD-L1, may help to define a new treatment strategy for SCLC. Development of new treatment strategies may improve prognosis and survival.
REFERENCES (38)
1.
Regzedmaa O, Zhang H, Liu H, et al. Immune checkpoint inhibitors for small cell lung cancer: opportunities and challenges. Onco Targets Ther 2019; 12: 4605-4620.
2.
Latimer KM, Mott TF. Lung cancer: diagnosis, treatment principles, and screening. Am Fam Physician 2015; 91: 250-256.
3.
Inamura K. Lung cancer: understanding its molecular pathology and the 2015 WHO Classification. Front Oncol 2017; 7: 193.
4.
George J, Lim JS, Jang SJ, et al. Comprehensive genomic profiles of small cell lung cancer. Nature 2015; 524: 47-53.
5.
Koinis F, Kotsakis A, Georgoulias V. Small cell lung cancer (SCLC): no treatment advances in recent years. Transl Lung Cancer Res 2016; 5: 39-50.
6.
Li Q, Yuan D, Ma C, et al. A new hope: the immunotherapy in small cell lung cancer. Neoplasma 2016; 63: 342-350.
7.
Gkika E, Benndorf M, Oerther B, et al. Immunohistochemistry and radiomic features for survival prediction in small cell lung cancer. Front Oncol 2020; 10: 1161.
8.
Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res 2020; 10: 727-742.
9.
Lantuejoul S, Sound-Tsao M, Cooper WA, et al. PD-L1 testing for lung cancer in 2019: perspective from the IASLC pathology committee. J Thorac Oncol 2020; 15: 499-519.
10.
Tsao MS, Kerr KM, Dacic S, Yatabe Y, Hirsch FR. IASLC atlas of PD-L1 immunohistochemistry testing in lung cancer. Editorial Rx Press, North Fort Myers 2017.
11.
Guleria P, Kumar S, Malik PS, et al. PD-L1 expression in small cell and large cell neuroendocrine carcinomas of lung: an immunohistochemical study with review of literature. Pathol Oncol Res 2020; 26: 2363-2370.
12.
Tsuruoka K, Horinouchi H, Goto Y, et al. PD-L1 expression in neuroendocrine tumors of the lung. Lung Cancer 2017; 108: 115-120.
13.
Ishii H, Azuma K, Kawahara A, et al. Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer. J Thorac Oncol 2015; 10: 426-430.
14.
Wang H, Li Z, Dong B, et al. Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors. Diagn Pathol 2018; 13: 30.
15.
Yu S, Jia M, Li Y, et al. Differential Expression of PD-L1 in central and peripheral and TTF1-positive and -negative small-cell lung cancer. Front Med (Lausanne) 2021; 7: 621838.
16.
Yoshimura A, Yamada T, Miyagawa-Hayashino A, et al. Comparing three different anti-PD-L1 antibodies for immunohistochemical evaluation of small cell lung cancer. Lung Cancer 2019; 137: 108-112.
17.
Oizumi S, Yoh K, Matsumoto S, et al .Assessment of PD-L1 expression and oncogenic gene status in patients with small-cell lung cancer: Immuno-oncology biomarker study in LC-SCRUM-Japan. J Clin Oncol 2019; 37: 8558.
18.
Kim HS, Lee JH, Nam SJ, et al. Association of PD-L1 expression with tumor-infiltrating immune cells and mutation burden in high-grade neuroendocrine carcinoma of the lung. J Thorac Oncol 2018; 13: 636-648.
19.
Eichhorn F, Harms A, Warth A, et al. PD-L1 expression in large cell neuroendocrine carcinoma of the lung. Lung Cancer 2018; 118: 76-82.
20.
Kasajima A, Ishikawa Y, Iwata A, et al. Inflammation and PD-L1 expression in pulmonary neuroendocrine tumors. Endocr Relat Cancer 2018; 25: 339-350.
21.
Ohtaki Y, Kaira K, Atsumi J, et al. Prognostic significance of PD-L1 expression and tumor infiltrating lymphocytes in large cell neuroendocrine carcinoma of lung. Am J Transl Res 2018; 10: 3243-3253.
22.
Yasuda Y, Ozasa H, Kim YH. PD-L1 Expression in small cell lung cancer. J Thorac Oncol 2018; 13: e40-e41.
23.
Inamura K, Yokouchi Y, Kobayashi M, et al. Relationship of tumor PD-L1 (CD274) expression with lower mortality in lung high-grade neuroendocrine tumor. Cancer Med 2017; 6: 2347-2356.
24.
Miao L, Lu Y, Xu Y, et al. PD-L1 and c-MET expression and survival in patients with small cell lung cancer. Oncotarget 2017; 8: 53978-53988.
25.
Takada K, Toyokawa G, Okamoto T, et al. An Immunohistochemical analysis of PD-L1 protein expression in surgically resected small cell lung cancer using different antibodies and criteria. Anticancer Res 2016; 36: 3409-3412.
26.
Yu H, Batenchuk C, Badzio A, et al. PD-L1 expression by two complementary diagnostic assays and mRNA in situ hybridization in small cell lung cancer. J Thorac Oncol 2017; 12: 110-120.
27.
Fan Y, Ma K, Wang C, et al. Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors. Onco Targets Ther 2016; 9: 6075-6082.
28.
George J, Fernandez-Cuesta L, Walter, V et al. Comparative analysis of small cell lung cancer and other pulmonary neuroendocrine tumors. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16 –20; New Orleans, LA. Philadelphia (PA): AACR. Cancer Res 2016; 76: 122.
29.
Schultheis AM, Scheel AH, Ozretiæ L, et al. PD-L1 expression in small cell neuroendocrine carcinomas. Eur J Cancer 2015; 51: 421-426.
30.
Pacheco J, Bunn PA. Advancements in small-cell lung cancer: the changing landscape following IMpower-133. Clinical Lung Cancer 2019; 20: 148-160.
31.
Kintsler S, Cassataro MA, Drosch M, et al. Expression of programmed death ligand (PD-L1) in different tumors. Comparison of several current available antibody clones and antibody profiling. Ann Diagn Pathol 2019; 41: 24-37.
32.
Liao Y, Yin G, Wang X, et al. Identification of candidate genes associated with the pathogenesis of small cell lung cancer via integrated bioinformatics analysis. Oncol Lett 2019; 18: 3723-3733.
33.
Kadara H, Scheet P, Wistuba II, et al. Early events in the molecular pathogenesis of lung cancer. Cancer Prev Res (Phila) 2016; 9: 518-527.
34.
Walser T, Cui X, Yanagawa J, et al. Smoking and lung cancer: the role of inflammation. Proc Am Thorac Soc 2008; 5: 811-815.
35.
Thunnissen E, Borczuk AC, Flieder DB, et al. The use of immunohistochemistry improves the diagnosis of small cell lung cancer and its differential diagnosis. An International Reproducibility Study in a demanding set of cases. J Thorac Oncol 2017; 12: 334-346.
36.
Kyriakopoulos G, Mavroeidi V, Chatzellis E, et al. Histopathological, immunohistochemical, genetic and molecular markers of neuroendocrine neoplasms. Ann Transl Med 2018; 6: 252.
37.
Iida Y, Masuda S, Nakanishi Y, et al. Clinicopathological characteristics of thyroid transcription factor 1-negative small cell lung cancers. Hum Pathol 2018; 79: 127-134.
38.
Lu D, Ni Z, Liu X, et al. Beyond T cells: understanding the role of PD-1/PD-L1 in tumor-associated macrophages. J Immunol Res 2019; 4: 1919082.
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
